Special Issue "Repurposing Drugs for Anti-Cancer Therapy"
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 10909
Interests: glioma; radiation physiology; electro- and Ca2+ signaling; ion channels in tumor biology; oncoimmunology
Special Issues, Collections and Topics in MDPI journals
Age-standardized cancer death rates are falling globally; however, there are still several cancer entities with very bad prognoses. While extensive scientific efforts have been undertaken to find new and effective treatments, such as checkpoints inhibitors, CAR-T cells, personalized cancer vaccination, targeting the tumour microenvironment, or direct interference with driver mutations, there are still plenty of examples showing no or very little improvement in prognosis. One prime example may be glioblastoma multiforme with a 5-year survival rate of around 5% and little progress in treatment and prognosis during the past decade.
One promising approach gaining more and more traction is to repurpose known drugs that are approved for other conditions after elucidating their interference with tumour biology. Examples of “repurposable” drugs of former or current clinical use that might broaden our approach to fight cancer are numerous. Among those are substances with well-defined preclinical anticancer efficacy such as disulfiram, a drug used to support the treatment of chronic alcoholism. Other drugs have attracted attention via retrospective clinical data of cancer patients, suggesting a correlation between a drug used for nononcologic indications and improved overall survival, as demonstrated for the antidiabetic drug metformin in colorectal cancer.
This process may streamline our efforts to well-tolerated drugs with favourable pharmacokinetic properties and hence reduce both time to initiate clinical trials and the costs of development. Moreover, through coordinated interference with several oncogenic pathways, repurposed drugs may help to tackle the heterogeneous nature of many cancers, with few severe adverse events expected.
In this Special Issue, we invite you to contribute both new basic findings about cancer pathway dependencies, already targeted in other diseases, and your exploratory or confirmatory studies testing repurposed drugs against the respective cancer entity. We are also interested in your critical contributions about potential pitfalls in this approach, leading to a comprehensive overview about repurposing ‘old’ drugs against cancer.
Prof. Stephan M. Huber
Mr. Nicolai Stransky
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2100 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.